SIM
VRDN icon

Spark Investment Management’s Viridian Therapeutics VRDN Stock Holding History

Spark Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-670
Closed -$64K – 747
2018
Q2 		$64K Buy
+670
New +$70.8K ﹤0.01% 627

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BWP
BSW Wealth Partners Boulder, Colorado $899M AUM 28.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spark Investment Management's VRDN Position: Q3 2018 in Review

Spark Investment Management sold out of Viridian Therapeutics (VRDN) in Q3 2018, closing a stake of 670 shares — an estimated $64K sold.

Spark Investment Management first reported a position in VRDN in Q2 2018 and held it in 1 quarter. The position peaked at $64K in Q2 2018. 57 funds tracked by Wall St. Rank hold VRDN as of Q3 2018.

  • Spark Investment Management reported no remaining Viridian Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Spark Investment Management sold 670 Viridian Therapeutics shares in Q3 2018, an estimated $64K.
  • Spark Investment Management first reported a position in Viridian Therapeutics in Q2 2018 and held it in 1 quarter.
  • Spark Investment Management's Viridian Therapeutics position peaked at $64K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2018.

Based on Spark Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.